Evaluation of the Frequency of (rs2227981 and rs2282055) Single Nucleotide Polymorphisms in Programmed Cell Death 1 and Its Ligand Genes of Iraqi Patients With Multiple Sclerosis
DOI:
https://doi.org/10.31351/vol33iss3pp209-217Keywords:
Keywords: Multiple sclerosis, polymorphism, PD-1, PD-L1, rs2227981, rs2282055.Abstract
Abstract
Multiple sclerosis (MS) is a central nervous system disease that causes demyelination and persistent inflammation and most of them among young adults.
The current study aimed to assess gene polymorphism of PDCD1 and PDLCD1 genes and the frequency of two SNPs (rs2227981 and rs2282055).
MS patients (n=100) were divided into two groups; newly diagnosed (42), and patients with ongoing treatments (58). These groups were compared to healthy subjects (n=55); the mean age ±SD was (30±8.46 years), (37±8.06years), and (31±8.73 years) for MS newly patients, patients with ongoing treatments, and healthy subjects, respectively. Studies for gene polymorphism of PDCD1 and PDLCD1 Genes and the Frequency of Two SNPs (rs2227981 and rs2282055) were measured by Real-time PCR by used HRM.
The results of this study found that the genotypic frequencies of MS patient were 31% (n=31) normal AA and 48 % (n=48) heterozygous AG. Mutant homozygous was found in GG 21 % (n=21). In controls, the results demonstrate 69% (n=38) wild type AA, 27.27% (n=15) heterozygous AG and mutant homozygous GG 3.6% (n=2). The odds ratio for the GG genotype was 12.8 (0.2-5.9) with p=0.001 indicating that the homomutant genotype In PD1 gene polymorphism rs2227981 GG was a higher risk of MS than the wild-type PD1 gene polymorphism rs2227981 AA, The PD1 gene polymorphism rs2227981 AG genotype has the second risk of MS after PD1 gene polymorphism rs2227981GG with 3.92 fold high risk than the wild type AA (OR =3.92 (1.8-8.2) p=0.0003).
The present study concludes that the population-based case-control study, which focused on the three PD-1 SNPs PD-1.3, PD-1.5, and PD-1.9, found that polymorphism variation might actually be a disease-modifying factor as opposed to an MS risk factor. There were substantially more PD-L1 gene SNP loci in MS patients compared to controls, and there were significantly more PD-L1 gene SNP loci in MS patients compared to controls. The pathogenesis of MS might be connected to PD-1 and PD-L1 SNPs. PD-L1 gene SNP locus rs2282055 and PD-1 gene SNP locus rs2227981 might be potential MS candidate polymorphism loci.
Received 2/8/2023
Accepted 11/10/2023
Published 15/9/2024
References
Höftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Neuropathology [Internet]. 2018;263–83. Available from: http:/ / dx. doi. Org /10. 1016 / b978 -0-12-802395-2.00019-5
Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. Multiple Sclerosis and Related Disorders [Internet]. 2019 May; 30:215–24. Available from: http:// dx. doi. Org /10. 1016/j.msard.2019.01.039
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain [Internet]. 2016 Oct 29; aww258. Available from: http://dx.doi.org/10.1093/brain/aww258
Bailey SM, Rice CM. Symptomatic Treatment for Progressive Multiple Sclerosis. Progressive Multiple Sclerosi . 2017; 11;155–205. http://dx.doi.org/10.1007/978-3-319-65921-3_7
Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. Rahimi K, editor. PLOS Medicine [Internet]. 2020;17(12): e1003432. http: // dx. doi. Org /10. 1371/ journal. pmed.1003432
Dobson R, Giovannoni G. Multiple sclerosis – a review. European Journal of Neurology . 2018 Nov 18;26(1):27–40.http:// dx. doi. org/ 10. 1111/ene.13819
Ortler S, Leder C, Mittelbronn M, Zozulya AL, Knolle PA, Chen L, et al. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. European Journal of Immunology. 2008; 18;38(6):1734–44. .http://d x .doi .org/ 10. 1002 /eji .200738071
Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Frontiers in Cellular Neuroscience. 2021; 15. http:// dx. doi. Org / 10.3389 /fncel .2021 .716747.
Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, Sevilla-Reyes E, Boll MC, Montes-Moratilla E, et al. Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs: other regulatory populations are also involved. Journal of Neuroinflammation. 2019;16(1). http://dx.doi.org/10.1186/s12974-019-1606-1
Albukhaty S, Al-Musawi S, Abdul Mahdi S, Sulaiman GM, Alwahibi MS, Dewir YH, et al. Investigation of Dextran-Coated Superparamagnetic Nanoparticles for Targeted Vinblastine Controlled Release, Delivery, Apoptosis Induction, and Gene Expression in Pancreatic Cancer Cells. Molecules. 2020;25(20):4721. http://dx.doi.org/10.3390/molecules25204721.
Rid A, Schmidt H. The 2008 Declaration of Helsinki - First among Equals in Research Ethics? Journal of Law, Medicine & Ethics. 2010;38(1):143–8. http://dx.doi.org/10.1111/j.1748-720x.2010.00474.x
Omerhoca S, Yazici Akkas S, Kale Icen N. Multiple sclerosis: Diagnosis and Differrential Diagnosis. Archives of Neuropsychiatry . 2018; http://dx.doi.org/10.29399/npa.23418.
Ayoib A, Hashim U, Gopinath SCB. Automated, high-throughput DNA extraction protocol for disposable label free, microfluidics integrating DNA biosensor for oil palm pathogen, Ganoderma boninense. Process Biochemistry .2020; 92:447–56. http://dx.doi.org/10.1016/j.procbio.2020.02.003.
Ali Jan M, Al-Saadi B, Al-Khafaji H, Al-Saedi M. Primer and Probe Designing to Detect SNP rs 4073 in Interleukin-8 Gene in Iraqi Patients with Bronchial Asthma. Journal of Applied Sciences and Nanotechnology. 2021;1(3):51–7. http://dx.doi.org/10.53293/jasn.2021.3542.1034
Garibyan L, Avashia N. Polymerase Chain Reaction. Journal of Investigative Dermatology [Internet]. 2013;133(3):1–4. http://dx.doi.org/10.1038/jid.2013.1
Gong R, Li S. Extraction of human genomic DNA from whole blood using a magnetic microsphere method. International Journal of Nanomedicine [Internet]. 2014;3781. http://dx.doi.org/10.2147/ijn.s59545
Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer. 2021 ;12(9) :2735–46. http:// dx. doi.Org /10.7150 /jca. 57334
Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. The Journal of Immunology. 2003;170(3):1257–66. http://dx.doi.org/10.4049/jimmunol.170.3.1257
Li C, Han X. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Pharmaceutical Research. 2020 May 31;37(6). http://dx.doi.org/10.1007/s11095-020-02838-4
Chen L, Pai V, Levinson R, Sharpe AH, Freeman GJ, Braun J, et al. Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis. Ocular Immunology and Inflammation .2009;17(1):47–55. http://dx.doi.org/10.1080/09273940802491884.
Pawlak-Adamska E, Nowak O, Karabon L, Pokryszko-Dragan A, Partyka A, Tomkiewicz A, et al. PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. Journal of Neuroimmunology. 2017; 305:115–27. http://dx.doi.org/10.1016/j.jneuroim.2017.02.006
Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Mäurer M, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology. 2005 23;58(1):50–7. http://dx.doi.org/10.1002/ana.20514
Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. The Journal of Immunology. 2009; 15;183(8):4984–93. http://dx.doi.org/10.4049/jimmunol.0901038
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Iraqi Journal of Pharmaceutical Sciences( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
